Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

NCT00091117 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

NIH

Sponsor class

Conditions

Hepatic Complications
Malignant Neoplasm

Interventions

DRUG: bortezomib
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)